Adaptive Biotechnologies Corp

NASDAQ:ADPT  
42.23
-1.45 (-3.32%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)5.68B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$27.82 Million
Adjusted EPS-$0.39
See more estimates
10-Day MA$50.11
50-Day MA$59.50
200-Day MA$48.95
See more pivots

Adaptive Biotechnologies Corp. Stock, NASDAQ:ADPT

1551 Eastlake Avenue East, Suite 200, Seattle, Washington 98102
United States of America
Phone: +1.206.659.0067
Number of Employees: 453

Description

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.